SCYNEXIS, Inc.

NasdaqCM:SCYX Stok Raporu

Piyasa değeri: US$56.4m

SCYNEXIS Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

SCYNEXIS yıllık ortalama 19.1% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 9.7% annual. Gelirler yılda ortalama 5.1% oranında büyüyor .

Anahtar bilgiler

19.06%

Kazanç büyüme oranı

37.48%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi5.95%
Gelir büyüme oranı5.13%
Özkaynak getirisi-59.35%
Net Marj-120.51%
Son Kazanç Güncellemesi31 Mar 2026

Yakın geçmiş performans güncellemeleri

Recent updates

Analiz Makalesi • Jan 23

Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Sep 09

Can SCYNEXIS (NASDAQ:SCYX) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • May 17

Here's Why SCYNEXIS (NASDAQ:SCYX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Aug 08

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analiz Makalesi • Jun 19

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

The SCYNEXIS, Inc. ( NASDAQ:SCYX ) share price has softened a substantial 32% over the previous 30 days, handing back...
Analiz Makalesi • May 12

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

It's been a good week for SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders, because the company has just released its latest...
Analiz Makalesi • Apr 04

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Apr 02

Scynexis: Update Following Restructuring Of GSK Deal

Summary Scynexis stock price has resumed the downtrend following a restructuring of the GSK deal associated with considerable reduction of pending milestones. SCYX ended 2023 with $98M, but is still trading at a $54M market cap. Cash runway is beyond 2 years, not accounting for pending milestones. Just the milestones from delivery of readouts to GSK and resumption and progress of MARIO trial are expected to cover all 2024 operating expenses. SCYX stock is undervalued in the short/medium term, but its long-term success is unclear considering emerging competition and pipeline limited to SCY-247. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 01

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

With a price-to-sales (or "P/S") ratio of 0.6x SCYNEXIS, Inc. ( NASDAQ:SCYX ) may be sending very bullish signals at...
Analiz Makalesi • Dec 21

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analiz Makalesi • Sep 26

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

SCYNEXIS, Inc. ( NASDAQ:SCYX ) shares have had a horrible month, losing 28% after a relatively good period beforehand...
Analiz Makalesi • Aug 17

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Aug 26

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Summary SCYX has a commercial antifungal Brexafemme. However, we are neutral on its commercial potential as discussed in our previous article. No big pharma deal materialized, and the company raised USD45M through pre-funded warrant offerings. The drug's true upside is in systemic fungal infection; however, catalysts are expected in 2024-2025 at the earliest making the stock uninvestible at this time. We downgrade SCYX to a sell rating. Background As described in detail in our initiation of coverage, we have established an option size position on SCYX based on a potential big pharma M&A and undoubtedly cheap valuation (negative EV) of the company. However, with the recent messy financing deal (described in detail below) and lack of near-term clinical catalyst, we decided to sell out of the position and downgrade the stock. Our rationale is described below. Catalysts are expected in 2024-2025 the earliest The absence of short-term catalysts makes it un-investible for short-mid-term investors in our view. We think the major value driver of the stock is in the systemic infection space, where the catalysts are expected in 2024-2025 (as shown below). Of note, the company announced that the FDA has accepted SCYX's submission of a supplemental New Drug Application regarding label expansion of BREXAFEMME to include "prevention of recurrent vulvovaginal candidiasis" and the target PDUFA date is Nov 2022. We believe the label extension is fully priced in and any positive news will be a selling opportunity for this ticker. SCYX Homepage Messy pre-funded warrants make SCYX uninvestible in our view SCYNEXIS priced its earlier announced underwritten public offering of 3.33M shares of its common stock, prefunded warrants to purchase 11.67M shares of common stock and warrants to purchase an aggregate of 15M shares of its common stock with gross proceeds expected to be ~$45M. The shares and warrants are being sold at $3.00/share and pre-funded warrants are offered at $2.999/pre-funded warrant and accompanying warrants. Underwriters over-allotment is an additional 2.25M of shares and/or warrants to purchase up to 2.25M shares of common stock. The warrants have a seven-year term and an exercise price of $3.45/share. -Source: Seeking Alpha News April 22 The company has a long history of raising capital through messy warrants which caused the stock to tank even after the approval of Brexafemme in June 2021 (as shown below); we believe the same thing is likely to happen with any positive catalyst making the stock uninvestible. Warrants could be a catastrophe as warrant holders can start exercising their warrants and sell into the market when a stock price move above a certain level and the exercised shares were sold into the market killing the share price. SCYX data by YCharts We believe the likelihood of a potential M&A has dropped considerably at this point.
Seeking Alpha • Aug 12

SCYNEXIS Q2 2022 Earnings Preview

SCYNEXIS (NASDAQ:SCYX) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$0.59 (-168.2% Y/Y) and the consensus Revenue Estimate is $1.64M Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Aug 01

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Scynexis (NASDAQ:SCYX) on Monday said the U.S. Food and Drug Administration (FDA) had accepted the biotech's supplemental new drug application (sNDA) to expand the label of its Brexafemme tablets to include the prevention of recurrent vulvovaginal candidiasis. Vulvovaginal candidiasis (VVC) is a type of yeast infection caused by the fungus candida which affects the vagina and the vulva. The company said the FDA had granted the sNDA submission a priority review and was set to decide on it by Nov. 30, or the so-called Prescription Drug User Fee Act date. Brexafemme is already approved to treat VVC. Recurrent VVC would be its second indication.
Seeking Alpha • Jul 19

SCYNEXIS gains after favorable data for antifungal agent in new indication

SCYNEXIS (NASDAQ:SCYX) added ~8% in the morning hours Tuesday after the commercial-stage pharma company announced promising Phase 3 data for its oral antifungal medication ibrexafungerp in patients with recurrent vulvovaginal candidiasis (RVVC). According to the data from the 24-patient CANDLE sub-study, ibrexafungerp, an FDA-authorized therapy for vulvovaginal candidiasis, has led to clinical benefits in RVVC patients who failed to respond to another antifungal therapy called fluconazole. After one day of ibrexafungerp (300 mg BID) treatment, 71% of RVVC patients (17 of 24) were found to have a significant reduction or elimination of signs and symptoms. Additionally, these results were replicated in a subset of patients who also demonstrated positive fungal cultures post-fluconazole treatment. In this 10-patient subgroup, 80% were found to have a favorable clinical response after one-day ibrexafungerp therapy. In June, SCYNEXIS (SCYX) announced the submission of its marketing application for the label expansion of ibrexafungerp in the prevention of RVVC. The supplemental New Drug Application was backed by data from the pivotal Phase 3 CANDLE, which indicated 65% clinical success for the treatment compared to ~53% for the placebo.
Analiz Makalesi • Apr 07

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Today is shaping up negative for SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders, with the analysts delivering a...
Seeking Alpha • Mar 07

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

We are initiating Scynexis with a target price of USD 23 per share. SCYX offers an extremely attractive set up with 600% upside and limited downside (10-15%) considering its near cash. SCYX's Brexafemme is clinically de-risked and targets an attractive fungal infection space. Even though we expect muted uptake during 2022, we project 200M-400M peak sales within 5 years. The critical inflection point for the stock will be a business development activity from Big Pharma, not near-term earnings. The company has 100M cash, but has a high cash burn rate of around 50M/year and will likely need to raise 50-100M soon to fund its phase 3 trials. Considering close to cash value EV, we view BD activity as more likely and a public offering.
Analiz Makalesi • Feb 13

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Market forces rained on the parade of SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders today, when the analysts downgraded...
Analiz Makalesi • Dec 03

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jul 27

Scynexis: Leading The Yeast Infection Treatment Industry

SCYNEXIS lead drug candidate BREXAFEMME recently got FDA approval for the treatment of Vulvovaginal Candidiasis, commonly known as vaginal yeast infections. BREXAFEMME is the first approved drug in the non-azole class for VVC and also the first approved drug in a novel antifungal class in the past 20+ years. The drug has ten years of market regulatory exclusivity and patent protection until 2035. The company’s financial position is robust, with adequate cash to commercialize BREXAFEMME while continuing its current studies.

Gelir ve Gider Dağılımı

SCYNEXIS nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:SCYX Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 2620-251529
31 Dec 2521-91422
30 Sep 253-251622
30 Jun 253-201525
31 Mar 253-271524
31 Dec 244-211426
30 Sep 249-361433
30 Jun 2410-351531
31 Mar 241401012031
31 Dec 23140672131
30 Sep 23136723228
30 Jun 23136444528
31 Mar 236-915328
31 Dec 225-636327
30 Sep 224-786227
30 Jun 223-496125
31 Mar 222-345823
31 Dec 2113-335024
30 Sep 2113-464026
30 Jun 2112-452830
31 Mar 2112-531934
31 Dec 200-551537
30 Sep 200-271337
30 Jun 200-361239
31 Mar 200-381139
31 Dec 190-541138
30 Sep 190-371034
30 Jun 190-291029
31 Mar 190-31926
31 Dec 180-12922
30 Sep 180-22820
30 Jun 180-31821
31 Mar 180-24820
31 Dec 170-25818
30 Sep 170-21817
30 Jun 170-24817
31 Mar 170-28719
31 Dec 160-30820
30 Sep 160-35922
30 Jun 160-311121
31 Mar 160-301217
31 Dec 150-281216
30 Sep 151-231213
30 Jun 151-191012

Kaliteli Kazançlar: SCYX şu anda kârlı değil.

Büyüyen Kar Marjı: SCYX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SCYX kârlı değildir, ancak son 5 yılda zararlarını yılda 19.1% oranında azaltmıştır.

Büyüme Hızlandırma: SCYX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: SCYX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( -5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: SCYX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -59.35% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/22 01:05
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

SCYNEXIS, Inc. 9 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Brian Kemp DolliverBrookline Capital Markets
Corey DavisCanaccord Genuity
Liisa BaykoCitizens JMP Securities, LLC